GHSR

JMV 3002 is a potent antagonist of the growth hormone secretagogue receptor (GHSR). It exhibits significant biological activity by inhibiting hexarelin-stimulated food intake in rat models, achieving up to 98% reduction at a dose of 80 μg/kg. JMV 3002 does not induce release of growth hormone on its own, nor does it inhibit hexarelin-stimulated growth hormone secretion in infant rats at a dose of 160 μg/kg. This compound is valuable for research focused on energy homeostasis and the regulation of appetite.

GHSR-1a agonist-1 is a potent agonist of the human growth hormone secretagogue receptor 1a (GHSR-1a), exhibiting an EC50 value of 0.49 nM. This compound effectively stimulates the release of endogenous growth hormone, making it valuable for investigating growth and developmental processes. In preclinical studies, oral administration at a dosage as low as 0.1 mg/kg led to significant increases in body weight and length in 4-week-old rats, supporting its potential applications in addressing growth and development retardation in pediatric research.

JMV 3008 is a GHS-R1a antagonist with an IC50 of 5.6 nM, effectively inhibiting the growth hormone secretagogue receptor 1a. This compound demonstrates potential in the study of metabolic disorders, including diabetes and obesity, by modulating appetite and energy homeostasis. Research involving JMV 3008 can contribute valuable insights into therapeutic strategies targeting these diseases.

KwFwLL-NH2 is a hexapeptide that functions as an inverse agonist at the growth hormone secretagogue receptor (GHSR). This compound demonstrates moderate potency with an EC50 of 45.6 nM, making it a valuable tool for investigating the role of ghrelin signaling in various biological processes. It is applicable in research focused on appetite regulation, metabolic disorders, and potential therapeutic interventions targeting the ghrelin pathway.